ArticleEuropean journal of case reports in internal medicine2026
Secondary Evans Syndrome Associated with Localized Clear Cell Renal Cell Carcinoma: A Case Report and Brief Literature Review.
Article in European journal of case reports in internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune thrombocytopenia (ITP) and autoimmune haemolytic anaemia (AIHA) are uncommon paraneoplastic manifestations of solid tumours, and their association with renal cell carcinoma is exceptional. Case description: A 66-year-old man with no prior medical history presented with profound thrombocytopenia (5 ×10 Conclusion: Secondary Evans syndrome associated with localized renal cell carcinoma is an exceptionally rare disorder. Persistence of cytopenias after surgical tumour control does not rule out a paraneoplastic mechanism, and TPO-RAs may represent an effective option in refractory cases, although evidence in secondary ITP remains limited. LEARNING POINTS: Secondary Evans syndrome (most commonly concurrent immune thrombocytopenia and autoimmune haemolytic anaemia) is an exceptionally rare paraneoplastic manifestation of localized clear cell renal cell carcinoma and requires rigorous diagnostic exclusion.Persistence of immune cytopenias for several weeks after curative nephrectomy does not exclude a paraneoplastic mechanism, as autoimmune activity may continue beyond tumour control.Thrombopoietin receptor agonists may be effective in immune thrombocytopenia secondary to solid tumours, a scenario with substantially less evidence than primary immune thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.